Scientific Sessions
  • #AHA22
  • Virtual Experience Access
  • Sessions Posters
  • Late-Breaking Science
  • Daily Coverage
  • Industry Highlights
  • Featured Exhibitors
  • Program
  • Previews
Topics
  • Late-Breaking Science
  • Daily Coverage
  • Industry Highlights
  • Featured Exhibitors
  • Program
  • Previews
Resources
  • #AHA22
  • Virtual Experience Access
  • Sessions Posters
User Tools
  • Privacy Policy
  • Terms & Conditions
  • Accessibility Statement
Twitter iconFacebook iconInstagram iconYouTube iconPinterest iconLinkedIn icon
Nov 13th, 2020

GALACTIC-HF results

Investigator John Teerlink, MD, FAHA, summarizes the results of GALACTIC-HF.


Investigator John Teerlink, MD, FAHA, summarizes the results of GALACTIC-HF, which found that improving cardiac function with omecamtiv mecarbil significantly reduced the risk of a first heart failure event or cardiac death in patients with heart failure with reduced ejection fraction.
Interesting Stories
MiCare Path joins the AHA CHTI and will integrate AHA science-based
Sponsored by MiCare Path
MiCare Path joins the AHA CHTI and will integrate AHA science-based
Modern Wearable Defibrillation
Sponsored by Kestra Medical Technologies
Modern Wearable Defibrillation
Data-driven precision medicine
Sponsored by Tempus
Data-driven precision medicine
New Double Take Videos from NEJM
Sponsored by NEJM Group
New Double Take Videos from NEJM
More Content
audience
AHA22
Early ablation bests medication in treatment naïve AFib patients
Nov 9th, 2022
audience shot
AHA22
First-in-class aminopeptidase-A inhibitor fails to reduce treatment-resistant hypertension
Nov 9th, 2022
audience shot
AHA22
Trial results shed light on tool for assessing VTE risk, routine anticoagulation for non-hospitalized COVID patients, and clinical outcomes of open vs. endovascular surgery for advanced PAD
Nov 8th, 2022
LBS 05 panelists
AHA22
Trials’ results highlight supplement ineffectiveness and potential for novel therapies to lower lipoprotein(a), reduce CKD progression
Nov 8th, 2022
audience shot
AHA22
Bivalirudin superior to unfractionated heparin in primary PCI following STEMI
Nov 8th, 2022
Panelists of the Mindful Disruption panel
Late-Breaking Science
Overcoming health disparities, health care advocates and mindfulness can better manage BP and CVD
Nov 7th, 2022
Person putting on tennis shows
AHA22
Join the Wellness Challenge at #AHA22
Oct 26th, 2022
Scientific Sessions attendees in lobby
Home
Join us for Scientific Sessions 2022 in Chicago or online
Sep 20th, 2022
Elaine Hylek, MD, MPH, and Bruno Caramelli, MD, PhD
AHA21
Trials’ results suggest advancements in treatment approaches for AF and insight on the cardiac effects of coffee consumption
Nov 19th, 2021
Lbs02 Group Blood Patel
AHA21
Update on local and global hypertension science
Nov 19th, 2021
(from left to right): Jonathan P. Piccini, MD, MHS, FAHA, and Steven A. Lubitz, MD, MPH, FAHA
AHA21
Late-Breaking Science: New information in cardiac disease
Nov 15th, 2021
(from left to right): Nasrien E. Ibrahim, MD, Stefan D. Anker, MD, PhD, and Clyde W. Yancy, MD, MSc, FAHA
AHA21
The latest science in heart failure
Nov 15th, 2021